The use of both levamisole & Isoprinosine has both synergistic and complementary effect in the treatment of COVID 19 infection
Study design: Randomized controlled trial, randomization by closed envelope technique
Informed consent will be written for each patient of either group
At the beginning of the study all patients will have the following investigations done: CBC
with differential, ESR, PCR for COVID 19, D dimer and CT chest and confirmed cases will
included in the study
Pregnant and lactating women together with children with other comorbidities will be excluded
from the study
Study groups:
Duration of the study is 4 weeks
Both groups with persistent COVID 19 symptoms that require hospitalization
Group 1: 30 patients with confirmed COVID19 infection and sharing clinical features like
fever, malaise, sore throat, runny nose, persistent cough &dyspnea, requiring hospitalization
Group 2: control group: 30 patients
Treatment endpoint • Cure of patients: Improvement of symptoms Laboratory findings ESR and
total leucocytic count returning to normal PCR negative Radiological improvement
• Worsening of symptoms or fatalities
Drug: Levamisole and isoprinosine
oral tablets levamisole 50 mg 3 times daily every other day for 2 weeks Isoprinosine oral tablets 1 g 4 times daily for 2 weeks
Other Name: ketrax and inosiplex
Drug: Azithromycin and hydroxychloroquine
oral tablets daily 500 mg azithromycin Oral tablets daily 200 mg hydroxychloroquine twice daily
Other Name: Zithromax and plaquinel
Inclusion Criteria:
- Confirmed COVID 19 infection (positive PCR, elevated ESR, leucopenia)
- Clinical picture of COVID 19 infection including fever, malaise, sore throat,
coughing, dyspnea, and runny nose
Exclusion Criteria:
- Mild cases of COVID 19 that do not require hospitalization
- Pregnant & lactating women
- Children with other comorbidities
- People who received previous treatment for COVID 19 in the last 2 weeks N.B. Diabetes
and hypertension not excluded
Hagar El Sayed, MD
0223682030
hgr_ntr@yahoo.com
Mohamed El Darouti, Professor
0223682030
Mohamed El Darouti, Professor, Principal Investigator
Cairo University